Study Comparing Two Durations of Epi-ON Corneal Crosslinking Using UVA Light for Treating Thinning Corneal Diseases

What this Trial Is About

This clinical trial studies the effects of a new treatment called corneal crosslinking CXL for eye conditions where the cornea becomes thin, steep, and misshapen, causing blurry vision. The trial focuses on patients aged 8 years and older diagnosed with keratoconus, ectasia after LASIK or PRK, pellucid marginal degeneration, progressive ectasia after previous CXL, or forme fruste keratoconus. The main goal is to find out if CXL can slow or stop the progression of these corneal diseases and prevent vision loss. Participants will receive CXL treatment where riboflavin Vitamin B2 eye drops is applied to the eye, followed by exposure to ultraviolet A UVA light. Two groups will be compared one group receives UVA treatment for 18 minutes and the other for 24 minutes, both with 15-second off-on cycling. The treatment aims to strengthen the cornea and stop disease progression. During the 6-month study, participants will attend up to 7 office visits for eye and vision tests. Researchers will measure corneal curvature using Kmax with the Pentacam and corrected distance visual acuity CDVA to evaluate effectiveness. Secondary measures include uncorrected visual acuity UCVA and possibly changes in higher order aberrations HOA and coma if wavefront testing is done. Safety and treatment effects will be monitored throughout the study period.

Comparison of Epi-ON Corneal Collagen Crosslinking Performed Using an 18-Minute UVA Exposure vs. a 24-Minute UVA Exposure on Eyes With Ectatic Corneal Diseases